From a clinical perspective, GPER disrupts the ER-centric, binary rubric which categorizes breast cancer as either estrogen responsive or nonresponsive, with nearly, 20% of all breast cancers expressing GPER in the absence of ER. The gene discussed is ESR1; the disease is breast cancer.